Insider · CIK 0001722753
Chirfi Guindo
directorofficer
Files at MRK (Merck & Co., Inc.), BEAM (Beam Therapeutics Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 4, 2025 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +36,903 | $79.29 | $2.9M | 107,409 | Aug 5, 2025 |
| Aug 4, 2025 | MRK Merck & Co., Inc. | FTax withholding Common Stock | -18,175 | $79.29 | $1.4M | 89,234 | Aug 5, 2025 |
| Aug 4, 2025 | MRK Merck & Co., Inc. | MOption exercise Restricted Stock Unitderivative | -36,903 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Jun 4, 2025 | BEAM Beam Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,662 | $0.00 | $0 | 33,662 | Jun 6, 2025 |
| Apr 29, 2025 | MRK Merck & Co., Inc. | AGrant or award Restricted Stock Unitderivative | +5,902 | $0.00 | $0 | 5,902 | May 1, 2025 |
| Apr 29, 2025 | MRK Merck & Co., Inc. | AGrant or award Stock Option (Right to Buy)derivative | +26,867 | $0.00 | $0 | 26,867 | May 1, 2025 |
| Jan 27, 2025 | MRK Merck & Co., Inc. | AGrant or award Common Stock | +28,158 | $97.94 | $2.8M | 69,144 | Jan 29, 2025 |
| Dec 2, 2024 | BEAM Beam Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +39,086 | $0.00 | $0 | 39,086 | Dec 4, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.